Broad Institute

JULY 19, 2023

Previous methods introduce millions of AAV capsids — the outer shells of the virus that bind to target proteins — into animals and rely on iterative rounds of screening to find AAVs that reach specific cells. Scientists have engineered adeno-associated viruses (AAVs) to package and deliver gene therapies to cells in the body.

Therapies 98

Therapies Research Engineering Virus 98

The Pharma Data

MARCH 2, 2021

Nasdaq: GILD) today announced the upcoming presentation of new data from the company’s HIV, hepatitis C virus (HCV), and COVID-19 research and development programs at the 28th Conference on Retroviruses and Opportunistic Infections ( virtual CROI 2021) taking place from March 6-10. Gilead Sciences, Inc. HIV Research. HCV Research.

Virus 40

Virus Treatment Science Trials 40

Drug Target Review

APRIL 17, 2024

HLA are the critical molecules that our immune systems use to present peptides to T cells and facilitate recognition and killing in immune responses to pathogens. HLA-II presents peptides to CD4 T cells thought to be important for indirectly helping immune responses and facilitating antibody production.

Immune Response 106

Immune Response Laboratories DNA Virus 106

Drug Target Review

JULY 5, 2023

In the study presented at ASGCT, what were the specific findings regarding the synergistic killing of SKOV3 ovarian tumour cells by the iPSC-derived lymphoid and myeloid cells? What are the key advancements in nucleic-acid delivery and targeted gene insertion that Eterna and Factor Bioscience presented at the ASGCT?

Therapies 104

Therapies DNA Engineering Virus 104

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. This press release features multimedia.

Trials 69

Trials Virus RNA Research Laboratories 69

Drug Target Review

AUGUST 25, 2023

However, in tissues where the 3 Hs are not present, the small molecule has anti-toxicity activity through 1) direct inhibition of the NLRP3 inflammasome, an inflammation starter and perpetuator, and 2) upregulation of the master antioxidant transcription factor, Nrf2. Also, unlike several other viruses, AdAPT-001 is deliverable systemically.

Small Molecule 98

Small Molecule Virus International Clinical Trials 98

The Pharma Data

DECEMBER 5, 2020

The data is being presented today in oral presentations at the 62nd American Society of Hematology (ASH) Annual Meeting. The new data presented today strengthen our conviction that SY-1425 has the potential to become the foundation of care for all RARA-positive patients,” said David A. Chief Medical Officer of Syros.

Clinical Trials 52

Clinical Trials Trials Small Molecule Treatment 52

PLOS: DNA Science

JANUARY 25, 2024

We can learn about life, past and present, anywhere we find DNA and determine its sequence. A recent report in PLOS ONE analyzes DNA from an adenovirus and a herpes virus discovered in preserved feces – coprolites – from 5,500 to 7,000 years ago at an archaeological site in Japan.

Disease 97

Disease DNA Science Virus 97

Drug Target Review

NOVEMBER 24, 2023

The use of nanoparticles, which are around the size of a virus particle, is a very promising delivery method for overcoming chemotherapy issues. Macrophages typically consume and clear pathogens and then present the pathogen parts to T cells. The T cells then give an antigen-specific response to recognise that specific pathogen.

Immune Response 111

Immune Response Pharmacy Treatment Virus 111

Drug Target Review

OCTOBER 25, 2023

Preeclampsia may present at any gestation but is more commonly encountered in the third trimester. A human foetus contains genetic material from both parents, which makes it partly foreign to the pregnant person’s body. Many of these adaptations happen within the decidua, tissue that surrounds and interacts with the placenta.

Treatment 106

Treatment Virus Research Science 106

FDA Law Blog: Drug Discovery

DECEMBER 7, 2022

Thus, the current reality of gene therapy products presents a conundrum to FDA: If you have an efficacious one-time treatment, how long do you wait to see if the treatment stops working or stops working as well, while patients receive very real benefits in the interim?

Therapies 119

Therapies FDA FDA Approval Treatment 119

The Pharma Data

OCTOBER 23, 2020

The conference featured presentations focusing on the latest advances in the relief of pain and total care of surgical patients prior to, during, and after surgery. By using PCR testing, the researchers identified that 102 of the 146 patients who verbally screened positive for COVID-19 were negative for the virus on PCR testing.

Virus 52

Virus Medical Schools Hospitals Research 52

The Pharma Data

NOVEMBER 11, 2020

“As an orally bioavailable small molecule with broad antiviral activity, SLV213 could be a valuable treatment to meet today’s urgent need to fight COVID-19 as well other life-threatening infectious diseases, such as Chagas disease, Ebola virus disease, and Nipah virus infection.”.

Treatment 52

Treatment Small Molecule Virus Pharmacokinetics 52

The Pharma Data

AUGUST 18, 2020

Experts suspect this is because the pandemic virus attacks nerve cells directly involved with smell and taste sensation. Anyone with these symptoms should self-isolate and arrange to have a swab test to check if they have the virus. The nose is one of the places where Sars-CoV-2, the virus that causes Covid-19, enters the body.

Virus 52

Virus Science Therapies Research 52

Creative Biolabs

JUNE 2, 2020

At present, this antibody, called S309, has entered the track of rapid development and testing in Vir Biotechnology, and clinical trials may be carried out in the next step. It can neutralize SARS-CoV-2 virus by binding to the S protein fragment near the attachment site of the host cell.

Virus 52

Virus Clinical Trials Research Treatment 52

The Pharma Data

JULY 6, 2021

If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, pieces scientists call epitopes. ” You can think of a virus’s structure like the design of a house, explains Nathan. .

Vaccine 52

Vaccine Virus Research Immune Response 52

Drug Target Review

SEPTEMBER 11, 2023

While the concept of removing mucins from cancer cells seems promising, mucins are present in various forms on all mammalian cells. Mucins are proteins covered in sugar that primarily protect the body against physical harm and pathogens. However, cancer cells exploit mucins to support their survival.

Immune Response 116

Immune Response Research Engineering Virus 116

Drug Target Review

SEPTEMBER 25, 2024

5 Here, the original oncogene is still present but the transdifferentiated cancer cells are less dependent on it. Investigating non-oncogene resistance as a parallel defense mechanism used by cancer cells to evade therapies could therefore present a significant opportunity to address drug resistance more comprehensively.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

The Pharma Data

MARCH 20, 2021

Patients with COVID-19 present with upper respiratory infections that can result in a number of complications particularly in patients of advanced age or with co-morbidities. Detection of virus-specific antibodies allows for diagnosis of recent symptomatic or even asymptomatic infections. INTRODUCTION.

Virus 52

Virus Assay Development Laboratories RNA 52

The Pharma Data

AUGUST 1, 2021

Problems with thinking were seen even in recovered COVID-19 patients who had only a mild cold or respiratory ailment after virus exposure, Dr. de Erausquin said. The olfactory bulb, which contains the brain cells that react to smell, is primarily where the COVID-19 virus enters the nervous system, Dr. de Erausquin said.

Virus 52

Virus International Science Disease 52

The Pharma Data

NOVEMBER 23, 2020

Trial participants to date are aged 18 years or over, who are healthy or have medically stable chronic diseases and are at increased risk for being exposed to the SARS-CoV-2 virus. Suspected cases presenting with compatible symptoms were tested for virological confirmation by COVID-19 PCR. AstraZeneca.

Vaccine 52

Vaccine Virus Trials Clinical Trials 52

DrugBank

MARCH 12, 2025

Once delivered into the body, the mRNA instructs cells to produce these antigens, which are then presented to the immune system. This customized approach is particularly valuable in oncology, where tumor heterogeneity presents significant challenges for traditional therapies.

Vaccine 97

Vaccine Treatment Clinical Trials Therapies 97

The Pharma Data

AUGUST 16, 2021

During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages. Clearance of the virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus.

Immune Response 52

Immune Response Vaccine Virus RNA 52

Fierce BioTech

JULY 17, 2023

png Listing Introduction In this presentation Mathias Kahl will refer about identified challenges, learnings and solutions during IDT AAV and LV manufacturing platform establishment. Sponsors are faced with a stark learning curve that, without intervention, may lead to high costs, delays, and a failure to bring their drug to patients.

Clinical Trials 52

Clinical Trials Virus Trials Therapies 52

The Pharma Data

JANUARY 22, 2021

Food and Drug Administration for use in early-stage COVID-19 patients with symptoms prevented COVID-19 infections in nursing residents and staff who were exposed to the virus, a new study shows. FRIDAY, Jan. 22, 2021 — An antibody drug that has emergency use authorization from the U.S. The New York Times Article. © 2021 HealthDay.

Nurses 52

Nurses Drugs Virus 52

Drug Target Review

SEPTEMBER 28, 2023

For security reasons, at the time COVID-19 had to be grown in BSL-3 labs, which can be dangerous because they were handling the live virus. These are synthetic, not the live virus, so do not pose a risk of infection. In 2020, BIO presented her with the Rosalind Franklin Award for Leadership.

DNA 116

DNA Organic Chemistry Science Virus 116

The Pharma Data

JULY 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials (MOVe-OUT and MOVe-IN) of molnupiravir (MK-4482/EIDD-2801), an investigational oral antiviral therapeutic. About Molnupiravir.

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories RNA 52

The Pharma Data

SEPTEMBER 1, 2020

of pupils in Scottish schools were present, down from a confirmed 95.8% “This may be the result of pupils and staff being isolated from others for a prolonged period, with the result that the virus is spreading more quickly now than schools have re-opened,” he added. Provisional figures from 28 August show that 84.5%

Government 52

Government Virus 52

The Pharma Data

OCTOBER 27, 2020

28, 2020 /PRNewswire/ — Pathnostics , a diagnostic solutions company, today announced that it has launched a multiplex polymerise chain reaction (PCR) test that simultaneously detects multiple respiratory infections, including COVID-19, influenzas A/B and respiratory syncytial virus (RSV). IRVINE, Calif. ,

Virus 52

Virus Disease Production 52

The Pharma Data

JUNE 25, 2021

The outcome confirms that only one single case was attributable to the original SARS-CoV-2 virus. “In addition, the variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge.” More than half of the cases (57%) were caused by Variants of Concern.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

NOVEMBER 24, 2020

One percent of those who received Xofluza compared with 13 percent who received placebo were infected with influenza and presented with fever and at least one respiratory symptom over 10 days. Individuals were randomly assigned to receive either a single dose of Xofluza (303 individuals) or placebo (304 individuals). More Information.

Virus 52

Virus FDA Trials Production 52

The Pharma Data

SEPTEMBER 16, 2020

FDA Commissioner Stephen Hahn had opposed the move because of the risks posed by the availability of unverified and potentially inaccurate tests during an ongoing pandemic, which could mean it complicates the US’ ability to respond to the virus’ spread. Matt Fellows. Source link.

FDA 52

FDA Virus Marketing Disease 52

The Pharma Data

DECEMBER 10, 2020

In the study, immunization with the hAd5-COVID-19 vaccine inhibited SARS-CoV-2 virus replication in 100% (10 of 10) of Rhesus macaques, with a drop in viral replication starting on the first day of vaccine administration, and undetectable viral levels as early as three to five days post-challenge in most of the animals.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

DECEMBER 16, 2020

NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. Additional terms of the agreement were not disclosed.

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

The Pharma Data

OCTOBER 18, 2020

The abstract presents the 12-month analysis of biomarkers and clinical outcome from the phase I/II trial in malignant pleural mesothelioma where ONCOS-102 is added to standard of care chemotherapy (pemetrexed / cisplatin). This analysis supports the data presented in June. OSLO, Norway , Oct. 361.

Virus 40

Virus Trials 40

The Pharma Data

AUGUST 3, 2020

Researchers said getting pupils back to school was important – but more work was needed to keep the virus in check. “Local health officials, using the latest data, will be able to determine the best action to take to help curb the spread of the virus should there be a rise in cases,” a statement said.

Government 52

Government Virus Research 52

The Pharma Data

NOVEMBER 23, 2020

Studies funded by a number of grants in the beginning of May are already providing insight into why the virus seems to affect the cardiac system, Lloyd-Jones said. 13 to 15 in Boston, will be presented in a hybrid format offering either in-person or virtual attendance. The meeting, to be held Nov. More Information. © 2020 HealthDay.

Research 52

Research Virus Therapies Trials 52